EIB Provides €20 Million in Financing to SamanTree Medical for Real-Time Microscopy for Surgical Procedures
27.1.2026 07:00:00 CET | Business Wire | Press Release
SamanTree Medical, a European leader in surgical imaging innovation, has secured €20 million in financing from the European Investment Bank (EIB). The operation is backed by InvestEU, the EU’s flagship program to mobilize over €372 billion in additional investment from 2021 to 2027.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126080876/en/
The European Investment Bank (EIB) provides €20 million in financing to SamanTree Medical, a leader in surgical imaging innovation. The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures, R&D and continued development and advancement of the company's Histolog® Scanner, the first and only medical imaging device featuring massively parallel confocal microscopy. Shown: Alessandro Izzo, EIB Director (left) and Olivier Delporte, CEO of SamanTree Medical (right).
The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures. Furthermore, the financing will support SamanTree Medical’s research, development and innovative activities, including continued development and advancement of its Histolog® Scanner
The EIB financing is provided through the Bank’s Venture Debt Instrument and is designed to support highly innovative companies undertaking research-intensive development activities.
“The support of the European Investment Bank represents an important milestone for SamanTree,” said Olivier Delporte, CEO of SamanTree Medical. “This financing allows us to accelerate development of the Histolog Scanner and expand our commercial presence across Europe and the United States. The rigorous due diligence process undertaken by the EIB reflects the importance of our innovative technology, our development plan and our long-term vision for advancing real-time, high-resolution imaging for excised tissue.”
“Our investment in SamanTree Medical reflects the EIB’s long-standing commitment to advancing medical innovation across Europe,” said EIB Director Alessandro Izzo. “By supporting med‑tech companies through venture debt, a tool that helps entrepreneurs accelerate growth and bring cutting-edge technologies to patients sooner, we make sure that key medical tech companies can grow and thrive in Europe. Supporting innovators like SamanTree Medical is central to our mission of driving positive impact for patients and healthcare systems.”
The advanced technique of the Histolog Scanner enables it to capture nearly 30,000 images simultaneously, rather than one at a time, producing high-resolution, histology-like images in approximately one minute without damaging the specimen. This allows surgeons and pathologists to image tissue within minutes and determine whether abnormal cellular microstructures remain at the surgical site, while patients remain on the operating table. Used in more than 6,000 patients to date, physicians using the Histolog Scanner have demonstrated compelling results across multiple tissue types. In breast-conserving surgery, the SHIELD study showed that when physicians used the Histolog images for assessment, reoperation rates were lowered from 30% to 10%, a 67% reduction.
Research has also shown that Histolog is similar1 when compared to intraoperative frozen-section analysis (the gold standard) for prostatectomies, while offering substantial time savings. Using Histolog for imaging and interpretation takes approximately 5-20 minutes, compared with 45-60 minutes for frozen section analysis.2 Using the Histolog images, physicians have also demonstrated a sensitivity ranging from 73% - 91% and a specificity ranging from 91% to 100%, when compared to conventional pathology.1,2,3 Additionally, studies have shown that intraoperative assessment allows surgeons to opt for more nerve-sparing surgeries, significantly reducing erectile dysfunction, a common side effect of a radical prostatectomy.4
Background
The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States.
Headquartered in Liège, Belgium, SamanTree Medical is a privately held company dedicated to improving oncologic surgery through innovative imaging solutions.
1https://pubmed.ncbi.nlm.nih.gov/39403832/
2https://pubmed.ncbi.nlm.nih.gov/36440864/
3IP8-FLUORESCE: A Prospective Paired Cohort Study Evaluating the Diagnostic Accuracy of Fluorescence Confocal Microscopy for Real-time Assessment of Surgical Margins in Radical Prostatectomy - PubMed
4https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00091-9/fulltext
View source version on businesswire.com: https://www.businesswire.com/news/home/20260126080876/en/
Contacts
Media contact
SamanTree: Amy Cook | +1 925 222 5094 | amy.cook@samantree.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo Group: Q1 Financial Results 2026/2713.8.2026 06:16:00 CEST | Press Release
Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported first quarter results for fiscal year 2026/27, marking the highest quarterly revenue growth in the past five years and the strongest quarter in the Group’s history. During the quarter, overall Group revenue reached an all-time quarterly high of US$26.9 billion, up 43% year-on-year, with all business groups delivering record first-fiscal-quarter revenue and operating profit. Adjusted net income[1]was up 176% year-on-year to US$1.1 billion, surpassing the US$1 billion milestone for the first time ever, with adjusted net margin improvements of almost two percentage points year-on-year supported by higher revenue scale and continued efficiency gains. AI-related revenue[2] grew 60% year-on-year to US$9.3 billion, accounting for 35% of total Group revenue in Q1. The Group continues to invest in innovation with R&D expenses up 30% year-on-year. The first quarter results demonstrate the G
Suzano Reports Adjusted EBITDA of R$4.7 Billion in the Second Quarter of 202613.8.2026 01:27:00 CEST | Press Release
Suzano, the world’s largest pulp producer, announces its results for the second quarter of 2026 (2Q26), reporting higher prices, stronger volumes and improvements in Adjusted EBITDA and operating cash generation compared to the previous quarter. The quarterly results reflect the competitiveness and resilience of Suzano’s operations in a quarter marked by foreign exchange headwinds and pressure on input costs driven by higher oil prices affecting the industry as a whole. Suzano sold 3.3 million tonnes of pulp and paper combined in 2Q26, comprising 2.9 million tonnes of pulp and 406 thousand tonnes of paper across the packaging, printing and writing, specialty and tissue segments. Net revenue totalled R$11.6 billion and adjusted EBITDA reached R$4.7 billion, both above the levels recorded in the previous quarter. Operating cash generation reached R$2.9 billion, while net income totalled R$1.8 billion in 2Q26. Despite ongoing cost pressures, the cash cost of pulp production (excluding dow
Moody’s Corporation Elects Keith Demmings to Board of Directors12.8.2026 22:15:00 CEST | Press Release
Moody’s Corporation (NYSE:MCO) today announced that Keith Demmings has been elected to the Company’s Board of Directors, effective November 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812902420/en/ Mr. Demmings, 54, currently serves as President and Chief Executive Officer of Assurant, Inc., a publicly traded company that safeguards and services connected devices, homes, automobiles, and commercial equipment in partnership with the world’s leading brands, a position he has held since January 2022. He has also served on Assurant’s Board of Directors since that time. Prior to his appointment as Chief Executive Officer, Mr. Demmings served as President of Assurant from 2021 to 2022, overseeing all operating segments, including Global Lifestyle and Global Housing. Earlier, he served as Executive Vice President and President, Global Lifestyle from 2016 to 2021, Executive Vice President and President, Global Markets
Lattice to Deliver Keynote at 2026 OCP Global Summit12.8.2026 22:00:00 CEST | Press Release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that Lattice will deliver a keynote at the 2026 OCP Global Summit. Ford Tamer, President and CEO of Lattice Semiconductor, will take the stage with Sanjoy Maity, Senior Vice President, AMI Business Unit Leader, Lattice Semiconductor. Together, they will discuss the growing need for a common management and control model for AI and compute infrastructure, and how the OCP Community can work together to bring this vision to life with existing open technologies. The keynote will take place on Tuesday, Oct. 13, 2026, at 10 a.m. PT at the San Jose Convention Center (SJCC), South Hall, San Jose, California. The OCP Summit is the premier event uniting the most forward-thinking minds in open IT Ecosystem development. The Summit presents a unique platform for the OCP community from around the globe to share their insights, foster partnerships, and showcase cutting-edge advancements in op
BM3EAC Corp. 2026 Semi-Annual Report12.8.2026 17:51:00 CEST | Press Release
BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2026 to 30 June 2026. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER The Company’s semi-annual report referenced in this announcement may include forward-looking statements, which are based on the Company's current expectations and projections regarding a business combination, the business, the economy and other future conditions of the Company and speak only as of the date hereof. Forward-looking statements may
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom